SI: the cashflow

MyFinsight

The latest financial statement is for the quarter ending 2025-09-30.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-09-30	2025-06-30
Gross profit	8,961	16,184
General and administrative	7,703	11,033
Sales and marketing	6,248	10,182
Medical education	1,126	2,136
Research and development	1,525	2,989
Interest/other expense	1,088	13,702
Net loss	-8,729	-23,858
Depreciation and amortization	843	1,385
Amortization of debt discounts	64	126
Stock-based compensation expense	298	317
Realized (loss) on marketable securities	195	207
Change in fair value of warrant liabilities and series e purchase option	-1,159	13,134
Change in fair value of convertible notes, net	2,216	-
Other	-67	-99
Trade accounts receivable	240	1,820
Inventory	2,277	3,126
Prepaid expenses	1,019	260
Accounts payable	807	982
Other current assets and liabilities	-769	-1,954
Net cash used in operating activities	-8,555	-11,274
Fixed asset purchases	2,815	2,311
Purchases of marketable securities	75,105	20,477
Sales of marketable securities	5,484	16,909
Net cash (used in) provided by investing activities	-72,436	-5,879
Proceeds from exercise of common stock options	537	151
Proceeds from exercise of preferred stock warrants	93	362
Proceeds from series e convertible preferred stock, net of issuance cost	-45	39,553
Proceeds from the issuance of convertible notes, net of issuance costs	39,863	-
Payment of deferred ipo offering costs	-	1,982
Proceeds from ipo, net of commissions and issuance costs	66,441	-
Net cash provided by financing activities	108,871	38,084
Net change in cash for period	27,880	20,931
Cash and cash equivalents at beginning of period	6,123	-
Cash and cash equivalents at end of period	54,934	-

Unit: Thousand (K) dollars